Images — A nose metastasis heralding renal cell carcinoma recurrence 25 years post-nephrectomy

Jesse Spooner, BSc1; Manjot Birk, BSc1; Davide Salina, MD2; Nathan Hoag, MD3

¹University of British Columbia Faculty of Medicine, Vancouver, BC, Canada; ²University of British Columbia, Department of Pathology, Victoria, BC, Canada; ³University of British Columbia, Department of Urologic Sciences, Victoria, BC, Canada

Cite as: Can Urol Assoc J 2020;14(3):E111-2. http://dx.doi.org/10.5489/cuaj.5905

Published online September 27, 2019

Introduction

Renal cell carcinoma (RCC) represents 2–3% of all cancers and 85% of primary renal tumors.¹ Approximately 20% of patients with RCC will have locally advanced disease, while 25% will have metastatic disease at diagnosis.¹ RCC will most commonly metastasize to the lungs, lymph nodes, bones, brain, and liver, with less common metastasis in the head and neck area.²-⁴ In one large study investigating the patterns of metastasis in different malignancies, no cases of RCC metastasis to the skin were noted.⁵ It is thought that up to half of patients with RCC will have distant metastases at some point, and when RCC recurs, it is typically within the first five years, but there are reports of metastasis in unusual distant sites beyond 10 years.³,6-8

Recently published Canadian guidelines for non-metastatic RCC followup emphasize the importance of surveillance and the use of pathological stage for the surveillance regimen.^{3,4} Risk-stratification is primarily based on pathological stage but should take into account other risk factors, such as histological subtype, Fuhrman nuclear grade, and clinical factors (including blood neutrophil to lymphocyte counts).³ The role of elevated neutrophils in promoting metastasis, including tumor-infiltrating neutrophils, in late-stage patients could be due in part to neutrophils acting as chaperones for circulating tumor cells via homing receptors to various distant metastatic sites, such as skin.^{9,10}

Case report

An 88-year-old, Caucasian male was seen for voiding symptoms. He had a history of open right radical nephrectomy for RCC 25 years prior. He was noted to have a fleshy

lesion on the tip of his nose, which had been present for several weeks and associated with minor bleeding (Fig. 1). The patient reported increasing fatigue over the past two months but did not report any other systemic symptoms. His neutrophil to lymphocyte was significantly elevated on complete blood count.

The patient underwent excisional biopsy of his nose lesion, which demonstrated a clear-cell carcinoma composed of alveolar nests of malignant clear cells surrounded by delicate capillary network with hemorrhage located within the dermis (Fig. 2A). Immunohistochemical stains were positive for A/E1/3, CK8/18, and Pax-8 — findings consistent with metastasis from patients with known RCC (Figs, 2B, 2C). Non-contrast computed tomography scan of the head/ neck/chest/abdomen/pelvis was performed, which demonstrated the secondary lesion of the nose, numerous pulmonary nodules, enlarged subcarinal lymph node, cerebellar lesions, and several soft tissue deposits of the body wall, and within the abdomen and pelvis. The patient was assessed by medical oncology and was started on systemic therapy with pazopanib at 50% dose. He was also assessed by radiation oncology and received palliative external beam radiation to the lesions on the nose, as well as one on his back.



Fig. 1. Clear-cell renal carcinoma metastasis to the tip of the nose 25 years post-nephrectomy.




Fig. 2. Pathologic findings of case. (A) 10X HE stained slide of skin metastasis; (B) Pax-8 positive immunolabeling; (C) pancytokeratin (AE1/AE3) positive immunolabeling.

Competing interests: The authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

References

- Vreudge S, Duttmann R, Halama A, et al. Metastasis of a renal cell carcinoma to the nose and paranasal sinuses. Acta Otorhinolaryngol Belg 1999;53:129-31.
- Dabestani S, Thorstenson A, Linblad P, et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: A population-based study. World J Urol 2016;34:1081-6. https://doi.org/10.1007/s00345-016-1773-y
- Kassouf W, Monteiro L, Drachenberg D, et al. Canadian Urological Association guideline for follow up after treatment of non-metastatic renal cell carcinoma. Can Urol Assoc J 2018;12:231-8. https://doi.org/10.5489/cuaj.5462

- Cheng ET, Greene D, Koch RJ. Metastatic renal cell carcinoma to the nose. Otolaryngol Head Neck Surg 2000;122:464. https://doi.org/10.1016/S0194-5998(00)70069-6
- Hu SC, Chen GS, Wu CS, et al. Rates of cutaneous metastasis from different internal malignancies: Experience from a Taiwanese medical center. J Am Acad Dermatol 2009;60:379-87. https://doi.org/10.1016/j.jaad.2008.10.007
- Abara E, Lolanda C, Nilam C, et al. Recurrent renal cell cancer: 10 years or more after nephrectomy. Can Ural Assoc J 2010;201:E45-9. https://doi.org/10.5489/cuaj.829
- Nagai T, Igase M, Ochi M, et al. Multiple metastases from renal carcinoma 15 years after nephrectomy. Nippon Ronene Igakkai Zasshi 2007;44:747-51. https://doi.org/10.3143/geriatrics.44.747
- Flamigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma. Cur Treat Options Oncol 2003;4:385-90. https://doi.org/10.1007/s11864-003-0039-2
- Tanaka N, Mizuno R, Yasumizu Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients
 with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy:
 A proposal of the modified-IMDC risk model. *Urol Oncol* 2017;35:39.e19-28.
- Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: Prognostic role and therapeutic strategies. Mol Cancer 2017;16:137. https://doi.org/10.1186/s12943-017-0707-7

Correspondence: Mr. Jesse Spooner, University of British Columbia Faculty of Medicine, Vancouver, BC, Canada; jesse.tr.spooner@gmail.com